Literature DB >> 22234582

Well differentiated thyroid carcinoma: current treatment.

J Kenneth Byrd1, Robert J Yawn, Christina S T Wilhoit, Nicoleta D Sora, Linda Meyers, Jyotika Fernandes, Terry Day.   

Abstract

OPINION STATEMENT: Well differentiated thyroid carcinoma (WDTC) is a relatively common malignancy accounting for an estimated 37,000 thousand cases in the United States in 2009 [1]. WDTC also has a generally high 5 year survival rate that correlates with age. Papillary thyroid carcinoma (PTC) greater than 1 cm is best managed by total thyroidectomy. Thyroid lobectomy and isthmusectomy may be adequate for unifocal PTC less than 1 cm in patients without negative prognostic factors. Central compartment and possible lateral neck dissections should be performed when nodal metastases are present in the respective nodal basins. Post-operatively, radioactive iodine ablation with (131)I followed by thyroid stimulating hormone (TSH) suppression is indicated in certain patients to improve locoregional control and reduce recurrence.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22234582     DOI： 10.1007/s11864-011-0173-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  45 in total

1.  Procedure guideline for therapy of thyroid disease with (131)iodine.

Authors:  Donald A Meier; David R Brill; David V Becker; Susan E M Clarke; Edward B Silberstein; Henry D Royal; Helena R Balon
Journal:  J Nucl Med       Date:  2002-06       Impact factor: 10.057

Review 2.  Thyroid-hormone therapy and thyroid cancer: a reassessment.

Authors:  Bernadette Biondi; Sebastiano Filetti; Martin Schlumberger
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2005-11

Review 3.  Anatomical and surgical considerations of the external branch of the superior laryngeal nerve: a systematic review.

Authors:  R P Morton; P Whitfield; S Al-Ali
Journal:  Clin Otolaryngol       Date:  2006-10       Impact factor: 2.597

Review 4.  Medical management of thyroid cancer: a risk adapted approach.

Authors:  R Michael Tuttle; Rebecca Leboeuf; Ashok R Shaha
Journal:  J Surg Oncol       Date:  2008-06-15       Impact factor: 3.454

Review 5.  Recurrent laryngeal nerve monitoring versus identification alone on post-thyroidectomy true vocal fold palsy: a meta-analysis.

Authors:  Thomas S Higgins; Reena Gupta; Amy S Ketcham; Robert T Sataloff; J Trad Wadsworth; John T Sinacori
Journal:  Laryngoscope       Date:  2011-05       Impact factor: 3.325

6.  Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis.

Authors:  Tarek Zetoune; Xavier Keutgen; Daniel Buitrago; Hasan Aldailami; Huibo Shao; Madhu Mazumdar; Thomas J Fahey; Rasa Zarnegar
Journal:  Ann Surg Oncol       Date:  2010-07-02       Impact factor: 5.344

7.  Consensus statement on the terminology and classification of central neck dissection for thyroid cancer.

Authors:  Sally E Carty; David S Cooper; Gerard M Doherty; Quan-Yang Duh; Richard T Kloos; Susan J Mandel; Gregory W Randolph; Brendan C Stack; David L Steward; David J Terris; Geoffrey B Thompson; Ralph P Tufano; R Michael Tuttle; Robert Udelsman
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

8.  Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience.

Authors:  E Baudin; J P Travagli; J Ropers; F Mancusi; G Bruno-Bossio; B Caillou; A F Cailleux; J D Lumbroso; C Parmentier; M Schlumberger
Journal:  Cancer       Date:  1998-08-01       Impact factor: 6.860

Review 9.  Novel molecular targeted therapies for refractory thyroid cancer.

Authors:  Cesar A Perez; Edgardo S Santos; Belisario A Arango; Luis E Raez; Ezra E W Cohen
Journal:  Head Neck       Date:  2011-05-04       Impact factor: 3.147

10.  Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.

Authors:  H Tala; R Robbins; J A Fagin; S M Larson; R M Tuttle
Journal:  J Clin Endocrinol Metab       Date:  2011-05-11       Impact factor: 5.958
View more
  5 in total

Review 1.  Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.

Authors:  Joshua J Gruber; A Dimitrios Colevas
Journal:  Oncologist       Date:  2015-01-23

Review 2.  Selectively false-positive radionuclide scan in a patient with sarcoidosis and papillary thyroid cancer: a case report and review of the literature.

Authors:  Nicole L Lebo; Francois Raymond; Michael J Odell
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-05-15

3.  A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.

Authors:  Qing Cheng; Xuechan Li; Chaitanya R Acharya; Terry Hyslop; Julie Ann Sosa
Journal:  Oncotarget       Date:  2017-03-07

4.  Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma.

Authors:  Liang Guo; Ya-Qi Ma; Yao Yao; Meng Wu; Zi-Hui Deng; Feng-Wei Zhu; Yu-Kun Luo; Jie Tang
Journal:  Sci Rep       Date:  2019-01-11       Impact factor: 4.379

5.  Coexistence of submandibular epithelioid angiosarcoma and papillary thyroid carcinoma: A case report.

Authors:  Yi-Ting Liu; Jing Wang; Yan-Xia Sui; Dong-Li Zhao
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.